Sprout Health

GLP-1 & Weight Loss

Written by AllyRx Editorial Team. Reviewed by Dr. [Name], MD. Last updated 12/3/2025

Verdict

Industry standard GLP-1 programs often raise prices as doses escalate. Sprout positions against that with flat-rate monthly and quarterly options that include the visit and shipping. Unlike competitors, it also lists tirzepatide tablets in addition to injections, plus a first-month discount. In contrast, transparency around service geography is mixed and a formal FDA warning letter dated September 9, 2025 flags marketing of compounded GLP-1s. For cost predictability and fast turnaround, Sprout is attractive, but patients prioritizing maximum regulatory certainty or brand medications may prefer alternatives or to wait for resolution. Coverage varies by state today.

Industry standard pricing in this category follows a tiered model where higher doses cost more. Sprout diverges with flat-rate pricing that includes the clinical consult and shipping, plus widely advertised first-month credits. Current GLP-1 plans list semaglutide at 249 dollars per month and tirzepatide at 299 dollars per month, with 50 dollars off the first month. A quarterly option lowers effective monthly costs. Unlike competitors, Sprout also promotes a “zero price increases” policy where the initial price is honored as doses rise. This put Sprout near the front on predictability while staying mid-market on headline price.

Industry standard clinical setups rely on national provider networks and a short asynchronous review. Sprout follows that template through a physician-only network partner and specifies states where synchronous visits are required. In contrast with many peers, its legal pages also name pharmacy partners. The company’s “About” page consistently notes compounded GLP-1s are not FDA-approved. The mix of clarity and caveats matters: it signals a legitimate telehealth framework while reminding patients these are compounded products dispensed by state-licensed pharmacies, not branded drugs.

Unlike competitors that quote loose shipping windows, Sprout’s flow details timing from consultation to doorstep. It advertises prescription decisions within 24 hours when appropriate, processing within two business days, then delivery within 3 to 7 business days. Cancellations are month-to-month: full refunds are allowed before a prescription is written; after processing, medications are non-refundable. Payments are cash-pay with major cards, and cancellation happens in-portal rather than by phone. This combination aligns with industry convenience standards while setting reasonable expectations on fulfillment.

In contrast to top-tier incumbents that emphasize brand drugs or have clean regulatory records, Sprout currently carries a significant asterisk. A formal FDA warning letter on September 9, 2025 addresses its online marketing of compounded semaglutide and tirzepatide. Separately, service availability messaging is inconsistent across legal pages, with one document listing exclusions and another listing all 50 states. For risk-averse patients or those wanting brand medications, these issues may be decisive. For cost-predictable compounding with fast access, Sprout remains competitive if these concerns are understood and acceptable.

Pros and Cons

Pros

Flat-rate pricing that does not rise with dose
First-month discount available on multiple funnels
Consultation and shipping included in listed price
Tirzepatide offered as injections and tablets
Quarterly plans available for additional savings
Typical decision in 24 hours with clear shipping timeline

Cons

Formal FDA warning letter issued September 9, 2025 regarding compounded GLP-1 marketing
Service geography messaging conflicts across legal pages
Compound-only pathway noted on site rather than brand drug fulfillment
No refunds after a prescription is processed; medications cannot be returned
Dose ranges and lab requirements not publicly detailed
Not available in certain states per current Terms

Our Research Methodology

Our investigation focused first on pricing and plan design. Across multiple landing pages, Sprout lists flat-rate GLP-1 plans: semaglutide at 249 dollars per month and tirzepatide at 299 dollars per month, with 50 dollars off the first month. A quarterly plan lowers the effective monthly cost, and the company promotes a zero-price-increases policy where initial pricing holds as doses rise. We verified that listed prices include the clinical consultation and shipping, aligning with the statement that all fees are presented at checkout.

Testing the care model and footprint, we reviewed Sprout’s Terms, which identify MD Integrations as the clinical network and specify states that require synchronous visits. The same section outlines state availability and exclusions. Pharmacy partners are named in legal notices, adding clarity to dispensing pathways. Separately, Sprout’s “About” page affirms that compounded GLP-1 products are not FDA-approved, which is standard for compounding disclosures. Together, these details depict a conventional telehealth structure with explicit partner visibility.

Operationally, we inspected onboarding, fulfillment, and cancellation language. Sprout states typical prescribing decisions within 24 hours when clinically appropriate, medication processing within two business days, and delivery within 3 to 7 business days. Cancellation is month-to-month: full refunds are available before the prescription is written; after a prescription is processed, medications are non-refundable and returns are not accepted. Payment is cash-pay and major cards are accepted. This policy set mirrors the category’s better operators on clarity.

Finally, we assessed risk signals and non-GLP-1 offerings. A formal FDA warning letter dated September 9, 2025 addresses Sprout’s online marketing of compounded semaglutide and tirzepatide. This is a meaningful compliance flag that patients should weigh. Beyond GLP-1s, Sprout offers compounded NAD+ therapy with first-month and three-month pricing and includes syringes and shipping. These ancillary offerings follow similar cash-pay, mail-order patterns.

Pricing

22 / 25

Sprout posts flat monthly rates: semaglutide $249 and tirzepatide $299, with a $50 first‑month credit and a quarterly option that lowers the effective monthly cost. Prices include the clinical consult and trackable shipping and are advertised as “no price increases” during titration. This compares favorably to dose‑tiered programs that climb as doses rise. Cash‑pay only; insurance isn’t accepted. Net: highly predictable out‑of‑pocket costs with mid‑market headline pricing.

Quality

8 / 20

Care is delivered through a physician network with named pharmacy partners; legal pages repeatedly note that compounded GLP‑1s are not FDA‑approved. State‑specific rules (e.g., synchronous visits where required) and pharmacy disclosure are positives for oversight and transparency. However, an FDA warning letter dated Sept 9, 2025 cites online claims around compounded semaglutide/tirzepatide; we weight this heavily. Clinical appropriateness screening appears standard for telehealth, but the regulatory posture lowers the safety‑compliance ceiling.

Onboarding

12 / 15

The intake is straightforward: medical history, contraindication screening, and ID. When eligible, a prescriber decision is typically returned within 24 hours; some states require a short synchronous visit. After approval, the pharmacy processes within ~2 business days and ships. Most patients see doorstep delivery in 3–7 business days. Cancellation is self‑serve in the portal and is fully refundable until a prescription is written.

Medication Options

11 / 15

Current offerings center on compounded semaglutide and tirzepatide, with injectables and select non‑injectable formulations depending on pharmacy availability. Dosing follows a titration ladder supervised by the clinician, and pricing is advertised as fixed across dose changes. Brand‑name GLP‑1s are not provided. NAD+ is also marketed as an add‑on plan. State availability messaging is inconsistent across legal pages; we defer to the newer Terms, but the discrepancy reduces confidence.

Shipping & Fulfillment

7 / 10

Sprout cites a typical path of approval within 24 hours (when appropriate), pharmacy processing in ~2 business days, then delivery in 3–7 business days. Orders include tracking, and timing can vary by pharmacy inventory and destination. Subscriptions are month‑to‑month; medications are non‑refundable once processing begins, with full refunds before a prescription is issued. Net consistency is in line with telehealth peers.

Customer Support

7 / 10

Support is email‑first with clinician messaging included in care. We didn’t find a posted phone line or live chat; response expectations appear within business hours. The portal handles cancellations and status updates, reducing back‑and‑forth. Coverage breadth of channels is adequate, though multi‑channel options would improve accessibility.

Usability & Experience

4 / 5

The application flow is clean and linear, with eligibility gating and clear next steps. Billing and shipment tracking are integrated, and cancellation is self‑serve. Content consistently distinguishes compounded from brand medications, which sets appropriate expectations. Overall UX meets or exceeds category norms with minimal friction.

Frequently Asked Questions

: Our investigation confirmed Sprout operates a conventional telehealth model with licensed clinicians and dispensing through named, state-licensed U.S. pharmacies. Its “About” material repeatedly clarifies that compounded semaglutide and tirzepatide are not FDA-approved products, which is standard for compounding. As of September 9, 2025, regulators issued a formal warning letter addressing the company’s online marketing of compounded GLP-1s. Patients should weigh that notice alongside the program’s pricing and access advantages and discuss risks, alternatives, and brand-drug options with a clinician before proceeding.
: Sprout lists flat-rate monthly plans that include the clinician visit and shipping. Current pricing: semaglutide at 249 dollars per month and tirzepatide at 299 dollars per month, each with 50 dollars off the first month. A quarterly plan is also available, and Sprout promotes price stability across dose increases. This contrasts with many programs that use dose-tiered pricing. All payments are cash-pay; insurance is not required. Review promotional pages for current codes and confirm whether quarterly billing aligns with your refill cadence.
: Sprout states that eligible patients receive a prescription decision within about 24 hours. After the prescription is written, orders are processed within two business days and delivered within 3 to 7 business days with trackable shipping. This meets or beats category averages for compounded fulfillment. Build in extra time for state-specific requirements and renewal steps. If timing is critical, confirm expected dates in your portal before the billing cycle renews.
: Our review found conflicting statements. A March 2025 Terms section lists availability with specific exclusions and also identifies states where synchronous visits are required. An earlier privacy page lists all 50 states. We weigh the newer Terms more heavily, but patients should verify eligibility during onboarding before paying. Despite the inconsistency, the platform outlines its clinical network and visit requirements, which helps set expectations.
: Sprout lists tirzepatide tablets alongside injections. These are compounded dosage forms, not brand oral GLP-1 products, and efficacy or absorption may vary compared with injections. Discuss route of administration, titration, side effects, and expected outcomes with your clinician. If predictability and published outcomes are priorities, an injectable GLP-1 pathway may align better with existing clinical data, while tablets may appeal to patients prioritizing convenience. Always align the choice with your medical history and the prescriber’s guidance.

Therapies offered & pricing comparison

GLP-1 & Weight Loss

Semaglutide (Compounded)

$249/month

Typical range: $166 – $299

$80$166$227$449

Type:

injection

Brand:

compound

Membership:

No separate membership - plan pricing includes consult and shipping

Price/Dose:

$249 (first month $199 with code)

Dose Range:

Not listed on site

Labs Required:

Not routinely required - clinician discretion

Notes:

Quarterly option $565 every 3 months; decision typically within 24 hours; delivery 3-7 business days.

Tirzepatide (Compounded)

$299/month

Typical range: $166 – $299

$80$166$227$449

Type:

injection

Brand:

compound

Membership:

No separate membership - plan pricing includes consult and shipping

Price/Dose:

$299 (first month $249 with code)

Dose Range:

Not listed on site

Labs Required:

Not routinely required - clinician discretion

Notes:

Quarterly option $700 every 3 months; price advertised as locked across doses.

Therapy

NAD+ (Compounded)

$249/month

Typical range: $149 – $169

$100$149$149$199

Type:

injection

Brand:

compound

Membership:

No separate membership - plan pricing includes consult and shipping

Price/Dose:

$249 after $199 first month

3.9 (9)

Pricing

4.4

Quality

3.5

Onboarding

4.7

Visit Website Read Review

Sort by

Most helpful review

Pavel S, Orlando, FL

Verdict

Frequently Asked Questions

Our investigation confirmed Sprout operates a conventional telehealth model with licensed clinicians and dispensing through named, state-licensed U.S. pharmacies. Its “About” material repeatedly clarifies that compounded semaglutide and tirzepatide are not FDA-approved products, which is standard for compounding. As of September 9, 2025, regulators issued a formal warning letter addressing the company’s online marketing of compounded GLP-1s. Patients should weigh that notice alongside the program’s pricing and access advantages and discuss risks, alternatives, and brand-drug options with a clinician before proceeding.

Sprout lists flat-rate monthly plans that include the clinician visit and shipping. Current pricing: semaglutide at 249 dollars per month and tirzepatide at 299 dollars per month, each with 50 dollars off the first month. A quarterly plan is also available, and Sprout promotes price stability across dose increases. This contrasts with many programs that use dose-tiered pricing. All payments are cash-pay; insurance is not required. Review promotional pages for current codes and confirm whether quarterly billing aligns with your refill cadence.

Sprout states that eligible patients receive a prescription decision within about 24 hours. After the prescription is written, orders are processed within two business days and delivered within 3 to 7 business days with trackable shipping. This meets or beats category averages for compounded fulfillment. Build in extra time for state-specific requirements and renewal steps. If timing is critical, confirm expected dates in your portal before the billing cycle renews.

Our review found conflicting statements. A March 2025 Terms section lists availability with specific exclusions and also identifies states where synchronous visits are required. An earlier privacy page lists all 50 states. We weigh the newer Terms more heavily, but patients should verify eligibility during onboarding before paying. Despite the inconsistency, the platform outlines its clinical network and visit requirements, which helps set expectations.

Sprout lists tirzepatide tablets alongside injections. These are compounded dosage forms, not brand oral GLP-1 products, and efficacy or absorption may vary compared with injections. Discuss route of administration, titration, side effects, and expected outcomes with your clinician. If predictability and published outcomes are priorities, an injectable GLP-1 pathway may align better with existing clinical data, while tablets may appeal to patients prioritizing convenience. Always align the choice with your medical history and the prescriber’s guidance.